ReviewClinical & translational immunology2019
Switching on the green light for chimeric antigen receptor T-cell therapy.
Review in Clinical & translational immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Scalable intracellular delivery via microfluidic vortex shedding enhances the function of chimeric antigen receptor T-cells.Scientific reports · 2025Article
- Scalable intracellular delivery via microfluidic vortex shedding enhances the function of chimeric antigen receptor T-cells.Research square · 2024Article
- Scalable intracellular delivery via microfluidic vortex shedding enhances the function of chimeric antigen receptor T-cells.bioRxiv : the preprint server for biology · 2024Article
- Targeting the Tumor Microenvironment in Acute Myeloid Leukemia: The Future of Immunotherapy and Natural Products.Biomedicines · 2022Review
- CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy.Nature communications · 2021Article
- IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors.Molecular therapy : the journal of the American Society of Gene Therapy · 2020Article
- Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity.Nature immunology · 2020Article
- The Immuno-Modulatory Effects of Inhibitor of Apoptosis Protein Antagonists in Cancer Immunotherapy.Cells · 2020Review
- CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions.Frontiers in oncology · 2020Review
- Tuning the performance of CAR T cell immunotherapies.BMC biotechnology · 2019Review
- Review
- CAR T cells take centre stage.Clinical & translational immunology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adoptive cellular therapy involving genetic modification of T cells with chimeric antigen receptor (CAR) transgene offers a promising strategy to broaden the efficacy of this approach for the effective treatment of cancer. Although remarkable antitumor responses have been observed following CAR T-cell therapy in a subset of B-cell malignancies, this has yet to be extended in the context of solid cancers. A number of promising strategies involving reprogramming the tumor microenvironment, increasing the specificity and safety of gene-modified T cells and harnessing the endogenous immune response have been tested in preclinical models that may have a significant impact in patients with solid cancers. This review will discuss these exciting new developments and the challenges that must be overcome to deliver a more sustained and potent therapeutic response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.